Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Adaptimmune Ther ADR (NQ: ADAP ) 1.080 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 290 Open 1.080 Bid (Size) 1.070 (43) Ask (Size) 1.080 (17) Prev. Close 1.080 Today's Range 1.080 - 1.080 52wk Range 0.4200 - 2.050 Shares Outstanding 1,480,950,456 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 12 Health Care Stocks Moving In Friday's After-Market Session April 19, 2024 Via Benzinga Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated April 12, 2024 Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader... Via Newsfile Performance YTD +44.77% +44.77% 1 Month -25.00% -25.00% 3 Month +51.05% +51.05% 6 Month +81.60% +81.60% 1 Year -18.18% -18.18% More News Read More Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet March 27, 2024 Via Newsfile Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday March 08, 2024 Via Benzinga Topics Stocks Exposures US Equities Adaptimmune Therapeutics Earnings Preview March 05, 2024 Via Benzinga Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session March 08, 2024 Via Benzinga ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023 March 06, 2024 Via InvestorPlace Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates March 06, 2024 Via Newsfile Topics Economy Exposures Product Safety Supply Chain Earnings Scheduled For March 6, 2024 March 06, 2024 Via Benzinga Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise February 27, 2024 Via Newsfile Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024 February 21, 2024 Via Newsfile 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 06, 2024 Via Benzinga Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review January 31, 2024 Via Newsfile Exposures Product Safety 12 Health Care Stocks Moving In Monday's After-Market Session January 29, 2024 Via Benzinga Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference January 04, 2024 Via Newsfile Exposures Product Safety 12 Health Care Stocks Moving In Friday's After-Market Session December 15, 2023 Via Benzinga Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma December 06, 2023 Via Newsfile Exposures Product Safety Adaptimmune Receives Transfer of IND for Lete-cel Program November 29, 2023 Via Newsfile Adaptimmune Reports Third Quarter Financial Results and Business Update November 08, 2023 Via Newsfile Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy November 08, 2023 Via Newsfile Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control October 31, 2023 Via Newsfile Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS October 31, 2023 Via Newsfile Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023 October 25, 2023 Via Newsfile Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO October 23, 2023 Via Newsfile Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development September 11, 2023 Via Newsfile Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.